UNSPSC 51181624: Calcitonin human

This classification denotes a peptide hormone with the molecular formula C151H226N40O45S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0IO929019, chemically known as calcitonin (human) [mart.], but more generally known as calcitonin human, which bears US NIH Compound Identifier 16132288. European Medicines Agency schedules calcitonin human or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00948MIG. Most nations, for tariff purposes, schedule calcitonin human under HS 29371900. SMILES:.

Calcitonin human bears US NLM identifiers UMLS ID C0770558 and NCI Concept Code C77142.

UNSPSC 51181624 Calcitonin human is a Commodity code representing pharmaceutical products supplied through cooperative purchasing agreements to state and local government facilities. State and local governments procure this product as part of broader generic multi-source pharmaceutical and over-the-counter (OTC) contracting frameworks that consolidate purchasing power across multiple jurisdictions and authorized drug wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for activity under this code. Solicitations target pharmaceutical manufacturers capable of supplying through established wholesale distribution channels, maintaining current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, and offering flexible pricing structures including flat price, net price formats, and WAC-minus arrangements. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and carry comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.

MMCAP operates as a multi-state vehicle with participation spanning Minnesota, Oregon, and other state and local government facilities. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026, seeking multiple awards for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. Awards will be effective July 1, 2026, for a two-year initial term with optional extensions at MMCAP's discretion. Evaluations emphasize price competitiveness (75 percent), with smaller weightings on fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). All products must be available in the marketplace by May 15, 2026, with minimum six-month shelf life and expiration dates of at least one year from manufacture.